Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
Jong‐Mu Sun(Samsung Medical Center), Dennis M. Frisman(Dana-Farber Cancer Institute), Russell Weiner(Mochida Pharmaceutical (Japan)), Young Mog Shim(CHA University Bundang Medical Center), Hong Kwan Kim(Samsung Medical Center), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yong Soo Choi(Samsung Medical Center), Se Eun Kim(Dana-Farber Cancer Institute), Marisa Dolled‐Filhart(Fox Chase Cancer Center), Dianna Wu(Memorial Sloan Kettering Cancer Center), Zhen Wang(Ministry of Education), So‐Jung Choi(Samsung Medical Center), Yoon‐La Choi(Samsung Medical Center), Wei Zhou(Broad Institute)
Cited by 156
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
|Journal of Clinical Oncology|2016|679